Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Sun Yat-sen University Chinese Academy of Medical Sciences Fudan University Cancer Center of Sichuan province Cancer Center of Fujian province Cancer Center of Guizhou province The First Affiliated Hospital of Guangxi Medical University Wuhan University |
---|---|
Information provided by: | Sun Yat-sen University |
ClinicalTrials.gov Identifier: | NCT00700440 |
This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Condition | Intervention | Phase |
---|---|---|
Nasopharyngeal Carcinoma |
Drug: C225 (cetuximab) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of Cetuximab Combined With IMRT and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma |
Estimated Enrollment: | 100 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 69 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tai-xiang Lu, M.D. | 86-20-873-4332 | lutx@mail.sysu.edu.cn |
Contact: Chun-yan Chen, M.D. | 86-20-873-4332 | sumsccy@163.com |
China, Guangdong | |
Cancer Center, Sun Yat-sen University | Recruiting |
Guangzhou, Guangdong, China, 510080 | |
Contact: Tai-xiang Lu, M.D. 86-20-8734-3372 lutx@mail.sysu.edu.cn | |
Contact: Chun-yan Chen, M.D. 86-20-8734-3372 sumsccy@163.com | |
Principal Investigator: Tai-xiang Lu, M.D. | |
Sub-Investigator: Chong Zhao, M.D. |
Principal Investigator: | Tai-xiang Lu, M.D. | Departments of Radiation Oncology, Cancer Center, Sun Yat-sen University |
Principal Investigator: | Tong-yu Lin, M.D., PhD | Departments of Chemotherapy, Cancer Center, Sun Yat-sen University |
Responsible Party: | Cancer Center, Sun Yat-sen University ( Departments of Radiation Oncology ) |
Study ID Numbers: | EMR62202-770, PPRA-RTOG 0001 |
Study First Received: | June 17, 2008 |
Last Updated: | July 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00700440 |
Health Authority: | China: Ethics Committee; China: Ministry of Health; China: State Food and Drug Administration |
Radiotherapy chemotherapy Drug Targeting |
loco-regionally advanced nasopharyngeal carcinoma Safety. efficacy |
Nasopharyngeal carcinoma Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Cisplatin Head and Neck Neoplasms Cetuximab |
Pharyngeal Neoplasms Stomatognathic Diseases Pharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Antineoplastic Agents |
Therapeutic Uses Nasopharyngeal Diseases Pharmacologic Actions |